Compare DCI & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DCI | PRAX |
|---|---|---|
| Founded | 1915 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Pollution Control Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.7B | 9.6B |
| IPO Year | 2005 | 2020 |
| Metric | DCI | PRAX |
|---|---|---|
| Price | $88.50 | $313.82 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 15 |
| Target Price | $99.00 | ★ $572.13 |
| AVG Volume (30 Days) | ★ 477.4K | 345.8K |
| Earning Date | 02-26-2026 | 05-01-2026 |
| Dividend Yield | ★ 1.35% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.75 | N/A |
| Revenue | ★ $2,844,900,000.00 | N/A |
| Revenue This Year | $4.58 | N/A |
| Revenue Next Year | $5.08 | $6,395.88 |
| P/E Ratio | $50.64 | ★ N/A |
| Revenue Growth | ★ 4.05 | N/A |
| 52 Week Low | $61.17 | $28.79 |
| 52 Week High | $112.84 | $354.87 |
| Indicator | DCI | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 50.10 | 52.61 |
| Support Level | $87.11 | $282.49 |
| Resistance Level | $94.26 | $327.65 |
| Average True Range (ATR) | 1.93 | 17.99 |
| MACD | 1.07 | 2.42 |
| Stochastic Oscillator | 82.20 | 64.57 |
Donaldson is a leading manufacturer of filtration systems and replacement parts (including air filtration systems, liquid filtration systems, and dust, fume, and mist collectors). The company serves a diverse range of end markets, including construction, mining, agriculture, truck, and industrial. Its business is organized into three segments: mobile solutions, industrial solutions, and life sciences. Donaldson generated approximately $3.7 billion in revenue in its fiscal 2025.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.